Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia August 23, 2020 Publications VIEW PUBLICATIONS ⟶ Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma October 1, 2019 Publications VIEW PUBLICATIONS ⟶ Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms March 21, 2019 Publications VIEW PUBLICATIONS ⟶ A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations August 25, 2018 Publications VIEW PUBLICATIONS ⟶ Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL August 22, 2018 Publications VIEW PUBLICATIONS ⟶ Minimal Residual Disease (MRD) Status Following Induction Chemo-Immunotherapy Predicts Progression-Free Survival In Mantle Cell Lymphoma (MCL): CALGB 50403 (Alliance) August 9, 2017 Publications VIEW PUBLICATIONS ⟶ T and B cell clonal expansion in Ras associated lymphoproliferative disease (RALD) as revealed by next generation sequencing May 30, 2017 Publications VIEW PUBLICATIONS ⟶ Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients May 2, 2017 Publications VIEW PUBLICATIONS ⟶ Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia May 2, 2017 Publications VIEW PUBLICATIONS ⟶ Clinical-scale Rapid Autologous BK-virus Specific T Cell Line generation from Kidney Transplant Recipients with Active Viremia for Adoptive Immunotherapy May 2, 2017 Publications VIEW PUBLICATIONS ⟶
Publications2019-09-18T18:25:31+00:00
FEATURED PUBLICATIONS

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

August 23rd, 2020|

VIEW PUBLICATION ⟶

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

March 21st, 2019|

VIEW PUBLICATION ⟶

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 25th, 2018|

VIEW PUBLICATION ⟶

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

August 22nd, 2018|

VIEW PUBLICATION ⟶

Targeted Deep Sequencing Reveals Clinically Relevant Subclonal IgHV Rearrangements in Chronic Lymphocytic Leukemia

October 31st, 2016|

VIEW PUBLICATION ⟶

LATEST PUBLICATIONS

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

August 23rd, 2020|

VIEW PUBLICATION ⟶

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

October 1st, 2019|

VIEW PUBLICATION ⟶

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

March 21st, 2019|

VIEW PUBLICATION ⟶

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 25th, 2018|

VIEW PUBLICATION ⟶

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

August 22nd, 2018|

VIEW PUBLICATION ⟶

Load More Posts
POSTERS

2019

AMP

2018

AMP
EHA

2017

AMP
EHA

2016

AMP

2015

AMP
EHA
LATEST PUBLICATIONS

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

August 23rd, 2020|

VIEW PUBLICATION ⟶

Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

October 1st, 2019|

VIEW PUBLICATION ⟶

Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

March 21st, 2019|

VIEW PUBLICATION ⟶

A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 25th, 2018|

VIEW PUBLICATION ⟶

Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

August 22nd, 2018|

VIEW PUBLICATION ⟶

Load More Posts
POSTERS

2019

AMP

2018

AMP
EHA

2017

AMP
EHA

2016

AMP

2015

AMP
EHA